RU2017105771A - Варианты дизинтегрина и их фармацевтическое применение - Google Patents
Варианты дизинтегрина и их фармацевтическое применение Download PDFInfo
- Publication number
- RU2017105771A RU2017105771A RU2017105771A RU2017105771A RU2017105771A RU 2017105771 A RU2017105771 A RU 2017105771A RU 2017105771 A RU2017105771 A RU 2017105771A RU 2017105771 A RU2017105771 A RU 2017105771A RU 2017105771 A RU2017105771 A RU 2017105771A
- Authority
- RU
- Russia
- Prior art keywords
- disintegrin
- mutant
- seq
- variant
- group
- Prior art date
Links
- 101800001224 Disintegrin Proteins 0.000 title claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims 6
- 102000006495 integrins Human genes 0.000 claims 6
- 108010044426 integrins Proteins 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 230000027455 binding Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 101000666940 Agkistrodon piscivorus piscivorus Disintegrin applaggin Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 1
- 101710096250 Lachesin Proteins 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- TTZWEOINXHJHCY-UHFFFAOYSA-N carapanaubine Natural products O=C1NC(C(=C(OC)C=C2)OC)=C2C11CCN2CC3C(C)OC=C(C(=O)OC)C3CC21 TTZWEOINXHJHCY-UHFFFAOYSA-N 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010070423 elegantin Proteins 0.000 claims 1
- TVCAZGSWNBZVJN-UHFFFAOYSA-M ethyl-[2-(2-hydroxy-2,2-diphenylacetyl)oxyethyl]-dimethylazanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C(O)(C(=O)OCC[N+](C)(C)CC)C1=CC=CC=C1 TVCAZGSWNBZVJN-UHFFFAOYSA-M 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 208000001491 myopia Diseases 0.000 claims 1
- 230000004379 myopia Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108010003419 saxatilin Proteins 0.000 claims 1
- -1 tergeminin Proteins 0.000 claims 1
- 108010028892 trimucrin Proteins 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- YEIGUXGHHKAURB-VAMGGRTRSA-N viridin Chemical compound O=C1C2=C3CCC(=O)C3=CC=C2[C@@]2(C)[C@H](O)[C@H](OC)C(=O)C3=COC1=C23 YEIGUXGHHKAURB-VAMGGRTRSA-N 0.000 claims 1
- 108010086097 viridin Proteins 0.000 claims 1
- YEIGUXGHHKAURB-UHFFFAOYSA-N viridine Natural products O=C1C2=C3CCC(=O)C3=CC=C2C2(C)C(O)C(OC)C(=O)C3=COC1=C23 YEIGUXGHHKAURB-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
Claims (20)
1. Вариант дизинтегрина, содержащий по меньшей мере один, выбранный из группы, состоящей из:
(a) мутантного линкера, содержащего по меньшей мере одну мутацию в положениях с 1 по 5 аминокислотной последовательности SEQ ID NO: 332 (SRAGKIC);
(b) мутантной петли RGD, содержащей аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NOs: 329-331; и
(c) мутантного С-конца, содержащего по меньшей мере одну мутацию в положениях с 1 по 4 аминокислотной последовательности SEQ ID NO: 334 (PRYH),
где вариант дизинтегрина имеет по меньшей мере одну пониженную активность связывания с интегрином 
и повышенную активность связывания по меньшей мере с одним из интегринов αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 и α5β1, по сравнению с дизинтегрином, не имеющим по меньшей мере одно, выбранное из группы, состоящей из мутантного линкера, мутантной петли RGD и мутантного С-конца.
2. Вариант дизинтегрина по п. 1, где дизинтегрин, выбран из группы, состоящей из родостамина, алболабрина, апплагина, басилицина, батроксостатина, битистатина, цереберина, церастина, кротатроксина, дуриссина, элегантина, флаворидина, флавостатина, халисина, халистатина, ярарацина, ярастатина, кистрина, лачесина, лутосина, молоссина, салмосина, саксатилина, тергеминина, триместатина, тримукрина, тримутаса, уссуристатина и виридина.
3. Вариант дизинтегрина по п. 1, содержащий мутантную петлю RGD, содержащую по меньшей мере одну мутацию в положениях 1-3, 5, 7 и 8 аминокислотной последовательности SEQ ID NO: 333 (RIPRGDMP) и по меньшей мере одно из мутантного линкера и мутантного С-конца.
4. Вариант дизинтегрина по п. 1, где мутантный линкер, содержит аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NO: 306 по SEQ ID NO: 318.
5. Вариант дизинтегрина по п. 1, где мутантный С-конец, содержит аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NO: 319 по SEQ ID NO: 328.
6. Вариант дизинтегрина по п. 1, содержащий мутантную петлю RGD, имеющую аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NO: 329 по SEQ ID NO: 331, и по меньшей мере одно из мутантного линкера, имеющего аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NO: 306 по SEQ ID NO: 318, и мутантного С-конца, имеющего аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NO: 319 по SEQ ID NO: 328.
7. Вариант дизинтегрина по п. 6, содержащий мутантную петлю RGD, мутантный линкер и мутантный С-конец.
8. Вариант дизинтегрина по п. 1, содержащий аминокислотную последовательность, выбранную из группы, состоящей из SEQ ID NOs: 123, 124, 147, 149 и 171.
9. Вариант дизинтегрина по п. 1, где вариант дизинтегрина является пегилированным или конъюгированным с альбумином или Fc.
10. Полинуклеотид, кодирующий вариант дизинтегрина по любому из пп. 1-9.
11. Рекомбинантная клетка-хозяин, содержащая полинуклеотид, кодирующий вариант дизинтегрина по любому из пп. 1-9.
12. Фармацевтическая композиция, содержащая вариант дизинтегрина по любому из пп. 1-9 и фармацевтически приемлемый носитель.
13. Способ лечения заболевания, связанного по меньшей мере с одним из интегринов, выбранных из группы, состоящей из αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 и α5β1, у субъекта, нуждающегося в этом, содержащий введение субъекту фармацевтической композиции по п. 12.
14. Способ по п. 13, где интегрин-ассоциированное заболевание является глазным заболеванием, связанным с ангиогенезом кровеносных сосудов, выбранным из группы, состоящей из возрастной макулярной дегенерации, диабетической ретинопатии, заболевания неоваскуляризации роговицы, индуцированной ишемией неоваскуляризированной ретинопатии, миопии высокой степени и ретинопатии недоношенных.
15. Способ по п. 13, где интегрин-ассоциированное заболевание является раковым заболеванием, выбранным из группы, состоящей из метастатической меланомы, метастатического рака простаты, метастатического рака молочной железы, колоректальной карциномы, рака печени, рака яичников, рака шейки матки, рака поджелудочной железы, немелкоклеточного рака легкого и мультиформной глиобластомы.
16. Применение варианта дизинтегрина по любому из пп. 1-9 в производстве лекарственного средства для лечения заболевания, связанного по меньшей мере с одним из интегринов, выбранных из группы, состоящей из αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 и α5β1, у субъекта, нуждающегося в этом.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040503P | 2014-08-22 | 2014-08-22 | |
| US62/040,503 | 2014-08-22 | ||
| PCT/US2015/046322 WO2016029131A1 (en) | 2014-08-22 | 2015-08-21 | Disintegrin variants and pharmaceutical uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017105771A3 RU2017105771A3 (ru) | 2018-09-24 |
| RU2017105771A true RU2017105771A (ru) | 2018-09-24 |
| RU2685869C1 RU2685869C1 (ru) | 2019-04-23 |
Family
ID=55351297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017105771A RU2685869C1 (ru) | 2014-08-22 | 2015-08-21 | Варианты дизинтегрина и их фармацевтическое применение |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10508137B2 (ru) |
| EP (1) | EP3182988A4 (ru) |
| JP (1) | JP6886917B2 (ru) |
| KR (1) | KR102102789B1 (ru) |
| CN (1) | CN106714818B (ru) |
| AU (1) | AU2015305299B2 (ru) |
| CA (1) | CA2958906C (ru) |
| MX (1) | MX2017002323A (ru) |
| RU (1) | RU2685869C1 (ru) |
| SG (1) | SG11201700114WA (ru) |
| TW (2) | TWI563001B (ru) |
| WO (1) | WO2016029131A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI563001B (en) * | 2014-08-22 | 2016-12-21 | Univ Nat Cheng Kung | Disintegrin variants and pharmaceutical uses thereof |
| CA2987884C (en) * | 2015-06-28 | 2023-01-03 | Allgenesis Biotherapeutics Inc. | Fusion peptides comprising disintegrin binding to integrin .alpha.v.beta.x or .alpha.5.beta.1 and their use in treating an angiogenic disease |
| IL247369B (en) * | 2016-08-18 | 2018-08-30 | B G Negev Tech And Applications Ltd | Polypeptides derived from CSF-m and their uses |
| EP3596105B1 (en) * | 2017-03-17 | 2023-12-27 | Technische Universität München | Ligands for integrin .alpha.v.beta.8, synthesis and uses thereof |
| EP3665190B1 (en) * | 2017-08-09 | 2023-07-26 | National Taiwan University | Disintegrin variants and uses thereof |
| US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5380646A (en) * | 1992-10-19 | 1995-01-10 | Temple University Of The Commonwealth System Of Higher Education | Thrombus detection using radiolabelled disintegrins |
| US7220724B2 (en) | 1993-10-22 | 2007-05-22 | University Of Southern California | Contortrostatin CN and methods for its use in preventing metastasis and other conditions |
| US7452551B1 (en) * | 2000-10-30 | 2008-11-18 | Imarx Therapeutics, Inc. | Targeted compositions for diagnostic and therapeutic use |
| US6926898B2 (en) * | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1620120A4 (en) * | 2003-03-24 | 2010-01-06 | Sequoia Pharmaceuticals Inc | BIOLOGICAL ACTIVE CONJUGATES WITH LONG-TERM EFFECT |
| US7943728B2 (en) * | 2006-12-26 | 2011-05-17 | National Cheng Kung University | Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases |
| US8183201B2 (en) | 2006-12-26 | 2012-05-22 | National Cheng Kung University | Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin |
| RU2547592C2 (ru) * | 2009-07-20 | 2015-04-10 | Нэйшнл Ченг Кунг Юниверсити | ПОЛИПЕПТИДЫ, СЕЛЕКТИВНЫЕ В ОТНОШЕНИИ ИНТЕГРИНА αvβ3, КОНЪЮГИРОВАННЫЕ С ВАРИАНТОМ ЧЕЛЕВЕЧЕСКОГО СЫВОРОТОЧНОГО АЛЬБУМИНА (HSA), И ИХ ФАРМАЦЕВТИЧЕСКИЕ ПРИМЕНЕНИЯ |
| US9044436B2 (en) * | 2009-12-23 | 2015-06-02 | National Cheng Kung University | Compositions and methods for the treatment of angiogenesis-related eye diseases |
| EP2910565A3 (en) * | 2010-02-11 | 2015-11-04 | University of Southern California | Modified ADAM disintegrin domain polypeptides and uses |
| US8946159B2 (en) * | 2011-12-22 | 2015-02-03 | California Northstate College Of Pharmacy, Llc | Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment |
| US20160317610A1 (en) * | 2013-09-25 | 2016-11-03 | University Of Southern California | Compositions and methods for treating ovarian cancer including preventing the recurrence thereof |
| TWI563001B (en) * | 2014-08-22 | 2016-12-21 | Univ Nat Cheng Kung | Disintegrin variants and pharmaceutical uses thereof |
| CA2987884C (en) * | 2015-06-28 | 2023-01-03 | Allgenesis Biotherapeutics Inc. | Fusion peptides comprising disintegrin binding to integrin .alpha.v.beta.x or .alpha.5.beta.1 and their use in treating an angiogenic disease |
-
2015
- 2015-08-21 TW TW104127347A patent/TWI563001B/zh active
- 2015-08-21 AU AU2015305299A patent/AU2015305299B2/en active Active
- 2015-08-21 KR KR1020177007653A patent/KR102102789B1/ko active IP Right Grant
- 2015-08-21 US US15/505,357 patent/US10508137B2/en active Active
- 2015-08-21 CN CN201580038532.7A patent/CN106714818B/zh active Active
- 2015-08-21 MX MX2017002323A patent/MX2017002323A/es unknown
- 2015-08-21 RU RU2017105771A patent/RU2685869C1/ru active
- 2015-08-21 EP EP15834216.2A patent/EP3182988A4/en active Pending
- 2015-08-21 TW TW105137246A patent/TWI579299B/zh active
- 2015-08-21 CA CA2958906A patent/CA2958906C/en active Active
- 2015-08-21 WO PCT/US2015/046322 patent/WO2016029131A1/en active Application Filing
- 2015-08-21 SG SG11201700114WA patent/SG11201700114WA/en unknown
- 2015-08-21 JP JP2017529973A patent/JP6886917B2/ja active Active
-
2019
- 2019-08-30 US US16/556,952 patent/US10870684B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2685869C1 (ru) | 2019-04-23 |
| KR20170042366A (ko) | 2017-04-18 |
| BR112017003334A2 (pt) | 2017-11-28 |
| JP6886917B2 (ja) | 2021-06-16 |
| WO2016029131A1 (en) | 2016-02-25 |
| RU2017105771A3 (ru) | 2018-09-24 |
| CN106714818A (zh) | 2017-05-24 |
| CA2958906A1 (en) | 2016-02-25 |
| JP2017525394A (ja) | 2017-09-07 |
| US10870684B2 (en) | 2020-12-22 |
| TWI579299B (zh) | 2017-04-21 |
| MX2017002323A (es) | 2017-08-02 |
| US20200010516A1 (en) | 2020-01-09 |
| US20170267731A1 (en) | 2017-09-21 |
| US10508137B2 (en) | 2019-12-17 |
| AU2015305299A1 (en) | 2017-02-09 |
| CA2958906C (en) | 2021-05-04 |
| KR102102789B1 (ko) | 2020-04-24 |
| BR112017003334A8 (pt) | 2018-02-06 |
| EP3182988A4 (en) | 2018-05-23 |
| TW201609793A (zh) | 2016-03-16 |
| TWI563001B (en) | 2016-12-21 |
| EP3182988A1 (en) | 2017-06-28 |
| SG11201700114WA (en) | 2017-02-27 |
| TW201708250A (zh) | 2017-03-01 |
| AU2015305299B2 (en) | 2018-11-01 |
| CN106714818B (zh) | 2020-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017105771A (ru) | Варианты дизинтегрина и их фармацевтическое применение | |
| Macêdo et al. | Disintegrins from snake venoms and their applications in cancer research and therapy | |
| JP2017525394A5 (ru) | ||
| RU2018146490A (ru) | Новые генно-инженерные вирусы осповакцины | |
| JP2014526441A5 (ru) | ||
| JP2015505843A5 (ru) | ||
| EA201790221A1 (ru) | Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii | |
| MY168536A (en) | Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin fc region | |
| JP2014138843A5 (ru) | ||
| Lucena et al. | Anti-invasive and anti-adhesive activities of a recombinant disintegrin, r-viridistatin 2, derived from the Prairie rattlesnake (Crotalus viridis viridis) | |
| Wu et al. | Targeting integrins in hepatocellular carcinoma | |
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| MY190257A (en) | Optimised subcutaneous therapeutic agents | |
| JP2013511559A5 (ru) | ||
| JP2015506352A5 (ru) | ||
| Hanasono et al. | Craniofacial reconstruction following oncologic resection. | |
| Celsa et al. | Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment | |
| JM | Collecting duct carcinoma of the kidney. A contribution of 4 new cases. | |
| Gautier et al. | Peripheral artery occlusive disease of the lower limbs: rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia | |
| JP2019524089A5 (ru) | ||
| Motamedi et al. | Peripheral and central giant cell granulomas of the jaws: a retrospective study and surgical management. | |
| CN208287299U (zh) | 防皮损静脉输液针头固定装置 | |
| JP2017531699A5 (ru) | ||
| Papp et al. | The role of neoadjuvant therapy in the treatment of locally advanced squamous cell cancer of the cervical oesophagus | |
| Glass | Psoriatic fingernail changes: case report |